Pink SheetAnticancer drugs continued to take up the lion's share of the novel drugs that gained approval in China in the first half of 2021, information compiled by the Pink Sheet based on official data shows
ScripIt will take only four more initial public offerings in the US by biopharmaceutical companies for 2020 to match the full-year total of 50 drug developer IPOs in 2019. First-time offerings by Kymera T
ScripBoth start-ups and established companies will benefit from 5AM Venture Management LLC's two new funds totaling $497m, increasing the San Francisco-based venture capital firm's capital raised to date t
ScripDerived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar